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INTRODUCTION
Gastrointestinal stromal tumors (GISTs) are usually resis-
tant to conventional chemotherapy. So, in case of unresectable
or metastatic GIST, the prognosis was poor. However the
prognosis of GIST has been changed dramatically after the
introduction of imatinib mesylate (Glivec, previously called
STI571). Imatinib inhibits not only bcr-abl tyrosine kinase
and platelet-derive growth factor (PDGF), but also c-KIT
kinase which is constitutively activated in GISTs. By this
reason, imatinib becomes to be wide use for the treatment
of GIST as well as chronic myeloid leukemia. Imatinib is
relatively safe drug comparing with conventional cytotoxic
drugs. Its adverse events were reported from several clinical
trials. Common adverse events were usually mild and included
nausea, edema, cramps, diarrhea, vomiting, rash, headache,
fatigue, and arthralgia (1-5). In addition, severe or rare adverse
events of imatinib have been reported, including severe skin
rash, hair repigmentation, splenic rupture, bone marrow necro-
sis, and male gynecomastia. We report here a case of male
gynecomastia coincident with testicular hydrocele in a patient
treated with imatinib for metastatic GIST. Gynecomastia
and testicular hydrocele are thought to be induced by ima-
tinib through inhibition of c-KIT and PDGF. We will dis-
cuss the possible mechanisms of gynecomastia and testicu-
lar hydrocele.
CASE REPORT
A 42-yr-old man visited our hospital for management of
liver masses. Two years earlier, he had undergone small bowel
resection for removal of a 20 cm-sized mass, later shown to
be a GIST. Following resection, he received postoperative
adjuvant radiation therapy, at a total dose of 5,040 cGy. Upon
presentation, multiple hepatic masses were revealed by com-
puted tomography (CT). A paraffin block specimen of the
previously resected small bowel mass was then reviewed. This
tumor consisted of polygonal to spindle cells with moderate
cellularity. The tumor cells showed pleomorphism, and necro-
sis was present. The mitotic figures were not frequent (2/50
high power fields). The tumor cells were immunohistochem-
ically positive for c-Kit and focally positive for SMA, but
negative for CD34 and S100, supporting the original diag-
nosis of GIST of interstitial cells of Cajal origin.
He was prescribed oral imatinib mesylate 400 mg daily.
Just after starting drug treatment, the patient complained
of periorbital swelling, but no dose reduction was required.
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Concurrent Male Gynecomastia and Testicular Hydrocele after Imatinib
Mesylate Treatment of a Gastrointestinal Stromal Tumor
We report a gastrointestinal stromal tumor (GIST) patient with male gynecomastia
and testicular hydrocele after treatment with imatinib mesylate. A 42 yr-old male
patient presented for management of hepatic masses. Two years earlier, he had
undergone a small bowel resection to remove an intraabdominal mass later shown
to be a GIST, followed by adjuvant radiation therapy. At presentation, CT scan re-
vealed multiple hepatic masses, which were compatible with metastatic GIST, and
he was prescribed imatinib 400 mg/day. During treatment, he experienced painful
enlargement of the left breast and scrotal swelling. Three months after cessation
of imatinib treatment, the tumors recurred, and, upon recommencing imatinib, he
experienced painful enlargement of the right breast and scrotal swelling. He was
diagnosed with male gynecomastia caused by decreased testosterone and non-
communicative testicular hydrocele. He was given androgen support and a hydro-
celectomy, which improved his gynecomastia. The mechanism by which imatinib
induces gynecomastia and hydrocele is thought to be associated with an inhibition
of c-KIT and platelet-derive growth factor. This is the first report, to our knowledge,
describing concurrent male gynecomastia and testicular hydrocele after imatinib
treatment of a patient with GIST.
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Three months later, the hepatic lesions improved, showing
a partial response, and nine months after his first visit to our
hospital, CT scan and positron-emission tomography showed
no evidence of disease. Treatment was discontinued after a
further 5 months of imatinib mesylate, but a CT scan per-
formed 3 months after finishing imatinib showed disease
progression. A second period of imatinib treatment was start-
ed, at the same dose of 400 mg/day. One month later, the
patient complained of breast pain and scrotal swelling. Physi-
cal examination revealed right gynecomastia and right pain-
less scrotal swelling. A precise medical history was taken, at
which point it was learned that left painful gynecomastia
and scrotal swelling had developed during the first period of
imatinib treatment, but that both had improved after stop-
ping imatinib. 
Pain in the right breast began on the 20th day of the sec-
ond period of imatinib treatment. Decreased libido and impo-
tence were noted. A testicular ultrasonogram showed a large
amount of fluid in the right scrotal sac and his right testis
was displaced downward (Fig. 1). The left scrotum and testis
and the bilateral spermatic cords were normal. The patient
was diagnosed with non-communicated testicular hydrocele.
The hormonal status of the patient was evaluated. Thyroid
function test was within normal ranges. His serum thyroid
stimulating hormone level was 1.1  U/mL, his free T4 con-
centration was 1.3 ng/dL, his serum luteinising hormone
level was 6.8 IU/L, and his follicle-stimulating hormone level
was 14.1 IU/L. His serum testosterone concentration had
decreased to 2.3 ng/mL. Androgen support was started and
hydrocelectomy was performed. Pathologic examination of
the hydrocele specimen showed it to be fibroadipose tissue
without lining mesothelium. His gynecomastia improved
after androgen support. 
DISCUSSION
The most common adverse events of imatinib mesylate
include edema, diarrhea, myelosupression, muscle cramps,
skin rash, and conjunctival inflammation, most of which are
mild (3, 6). In addition, rare or severe adverse events were
reported. There have been case reports of severe skin rash,
Stevens-Johnson syndrome, and an acute generalized exan-
thematous pustulosis in patients treated with imatinib (7, 8),
and 9 patients (5 men and 4 women) with gray hair before
treatment had progressive repigmentation during imatinib
treatment (9). In contrast to the repigmentation, imatinib
mesylate-induced hypopigmentation was also reported (10-
12). Among the more than 10,000 chronic myeloid leukemia
(CML) patients treated with imatinib, there have been 3
reported cases of splenic rupture (13), and bone marrow necro-
sis (14), possibly due to increased apoptosis and the release
of prothrombotic cellular material, has been reported. Imatinib
was originally developed for inhibition of bcr-abl tyrosine kinase.
However it is known that imatinib can also inhibit c-KIT
tyrosine kinase and platelet-derived growth factor receptor
(PDGFR) tyrosine kinase. The inhibition of c-KIT or PDGF
is thought to be responsive for some of these adverse events.
A recent report has described seven cases of gynaecomastia
(one grade 1 and six grade 2) in 38 CML patients treated with
imatinib (15). PDGF signaling is important in testes organo-
genesis and Leydig cell differentiation (16). Also, PDGF-A
is obligatory for adult Leydig cell recruitment and spermato-
genesis (17). c-Kit activity is modulated by stem cell factor
which in combination with insulin-like growth factor had
effect on leuteinizing hormone receptor and increased the
expression of StAR, CYP11A, CYP17, and 3 -hydroxys-
teroid dehydrogenase mRNA expression (18). Therefore,
imatinib can reduce testosterone biosynthesis by inhibiting
c-KIT and PDGFR in the testis, and male gynecomastia can
result from decreased testosterone (19, 20). In previous report,
rise of progesterone and 17-hydroxyprogesterone could rep-
resent the accumulation of testosterone precursors as a con-
sequence of impairment of key enzymes in the steroidogenic
cascade (15). In our report, decreased testosterone was detect-
ed during gynecomastia, and testosterone supply improved
gynecomastia and libido. 
In our patient, the relationship between imatinib therapy
and testicular hydrocele is evident by the fact that testicular
hydrocele was repeatedly developed during imatinib thera-
py and improved after ceasing imatinib. The mechanism by
which imatinib induces testicular hydrocele, however, is not
clear, although it may arise through same mechanism of edema
or fluid retention. Edema is the one of the most frequently
reported adverse events, most of which are well tolerated.
Unusual or severe cases of edema after imatinib such as cere-
bral edema, pleural effusion and severe periorbital edema were
also reported (21-23). The mechanism of edema induced by
imatinib is thought to be related with PDGFR. Signaling
Fig. 1. Ultrasonographic finding of testicular hydrocele. There is a
large amount of fluid in the right scrotal sac, and the right testis is
displaced downwardly. There was no evidence, however, of any
other mass.
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through PDGF- receptors increases interstitial fluid pres-
sure in the dermis (24, 25). On the contrary, inhibition of
PDGF reduces interstitial hypertension and increases tran-
scapillary transport in colonic carcinoma model (26). These
studies suggested that the inhibition of PDGFR by imatinib
is the possible mechanism of localized edema. Further inves-
tigation of the ability of imatinib to induce testicular hydro-
cele is warranted. To our knowledge, this is the first report
of male gynecomastia and concurrent testicular hydrocele fol-
lowing imatinib treatment of a patient with GIST.
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